OncoCyte Corp (NYSE:OCX) has earned an average broker rating score of 1.00 (Strong Buy) from the three analysts that provide coverage for the company, Zacks Investment Research reports. Three equities research analysts have rated the stock with a strong buy recommendation.
Brokers have set a 12 month consensus price objective of $10.33 for the company and are predicting that the company will post ($0.11) earnings per share for the current quarter, according to Zacks. Zacks has also assigned OncoCyte Corp an industry rank of 111 out of 265 based on the ratings given to its competitors.
Separately, Zacks Investment Research lowered shares of OncoCyte Corp from a “hold” rating to a “sell” rating in a research note on Thursday, September 15th.
Shares of OncoCyte Corp (NYSE:OCX) opened at 4.48 on Friday. OncoCyte Corp has a 12 month low of $2.45 and a 12 month high of $10.24. The firm’s market cap is $113.93 million. The company has a 50-day moving average of $4.54 and a 200-day moving average of $4.42.
OncoCyte Corp (NYSE:OCX) last issued its earnings results on Thursday, August 11th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.01. Equities analysts forecast that OncoCyte Corp will post ($0.43) EPS for the current fiscal year.
OncoCyte Corp Company Profile
OncoCyte Corporation is a development-stage biotechnology company focused in the field of regenerative medicine. The Company is developing molecular cancer diagnostics utilizing a discovery platform that focuses on identifying genetic markers expressed in various types of cancer. It operates through the research and development of diagnostic tests for the detection of cancer segment.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OncoCyte Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte Corp and related companies with MarketBeat.com's FREE daily email newsletter.